Venlafaxine Hydrochloride Extended-Release Articles
US FDA approves Teva’s generic venlafaxine, the first copy version of Pfizer’s Effexor XR
30 June 2010
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
Mylan gets US appro for generic Effexor
24 November 2008
Wyeth and Impax reach Effexor accord
28 July 2008
Wyeth moves into profit but disapoints
6 February 2006
Wyeth launches Effexor patient support campaign
22 August 2005
Stock Commentary - New York
7 February 2005
Lundbeck's Cipralex as effective as rival drug
21 June 2004
Wyeth posts 9% rise in 1st-qtr revenue
3 May 2004
Wyeth and Solvay enter CNS collaboration
12 April 2004
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Forest's Lexapro "has benefit over Effexor"
29 September 2003
Stock Commentary - New York
5 August 2002
AHP overcomes fen-phen problems to post strong growth for 2001
4 February 2002
AHP takes $950 mill fen-phen charge
24 October 2001
AHP posts 16% 1st-qtr earnings rise, sales up 6%
25 July 2001
New drug sales boost AHP's 1st-qtr profits
26 April 2001
AHP takes $7.5 billion charge for fen-phen
26 January 2001
AHP reaping benefits of R&D spend
20 October 2000
AHP posts healthy 2nd quarter results
24 July 2000
AHP posts 18% net income growth
20 April 2000
Effexor "more effective" than Prozac, says study
17 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
New indication for AHP's Effexor XR
12 March 1999
Effexor Shows Rapid Onset Of Efficacy Versus Prozac
6 November 1998
AHP Looks To Bright Future With New Products
30 April 1998
Showing 1-40 of 40 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
